Use of the composition

Abstract

The present invention relates to the use of a composition, more specifically to the use of a composition in the manufacture of a product for the relief of allergy and / or improvement of eczema, wherein the composition comprises medium-long chain fatty acid triglycerides and 2'-fucosyllactose, and the mass ratio of the medium-long chain fatty acid triglycerides to the 2'-fucosyllactose is 0.417 to 15.

Description

Technical Field

[0001] This invention relates to the use of compositions, and more particularly to the use of compositions in the preparation of products for relieving allergies and / or improving eczema. Background Technology

[0002] Eczema (atopic dermatitis) affects 10% to 20% of children worldwide. Itching is the most common symptom of eczema; repeated scratching causes skin damage, secondary infections, and pigmentation, resulting in severe physical and psychological distress for patients. The pathogenesis of eczema is closely related to the interaction of many factors, including genetic background, environmental factors, skin barrier dysfunction, microbial imbalance, immune dysregulation, and skin inflammation.

[0003] Allergic diseases are a group of illnesses caused by an abnormal or excessive response of the immune system to normally harmless environmental antigens (such as pollen, dust mites, and food proteins). These diseases exhibit a clear age-dependent evolutionary pattern, known as the "atopic process," manifesting primarily as atopic dermatitis (eczema) in early life, which may subsequently develop into allergic rhinitis, asthma, and food allergies. Mast cells (MCs) play a central role in type I hypersensitivity reactions (i.e., immediate-type anaphylaxis), primarily triggering degranulation through a signaling cascade mediated by high-affinity IgE receptors (FcεRI), releasing inflammatory mediators such as proteases and cytokines, and inducing typical allergic symptoms such as vasodilation, smooth muscle contraction, mucus secretion, and itching.

[0004] Some studies have suggested that 2'-fucosylated lactose (2'-FL) has the effect of relieving allergic reactions. For example, CN109731000B discloses that 2'-FL can relieve allergic reactions induced by β-lactoglobulin; CN114886119B discloses the allergic effect of 3'-sialyl lactose and its combination with 2'-FL in sensitized mice, suggesting that 2'-FL may have the ability to improve the symptoms of atopic dermatitis to some extent, but there is no direct research evidence to prove that 2'-FL can improve eczema.

[0005] Currently, there are no studies on the effects of medium- and long-chain triglycerides (MLCT) on alleviating allergies and / or improving eczema.

[0006] Furthermore, no studies have yet published on the efficacy of the combination of medium- and long-chain fatty acid triglycerides and 2'-fucosylated lactose in relieving allergies and / or improving eczema.

[0007] Moreover, no existing technology teaches that medium- and long-chain fatty acid triglycerides and 2'-fucosylated lactose can produce a synergistic effect in relieving allergies and / or improving eczema.

[0008] Currently, topical corticosteroids are the first-line treatment for eczema, primarily working through their anti-inflammatory effects. However, prolonged or improper use can lead to local side effects such as skin atrophy, telangiectasia, and pigmentation, with higher risks on the face and in skin folds.

[0009] In conclusion, there is still a need in this field to develop solutions that can more safely and effectively relieve allergies and improve eczema. Summary of the Invention

[0010] This invention was made in view of the above-mentioned problems existing in the prior art.

[0011] The present invention provides the use of a composition in the preparation of a product for relieving allergies and / or improving eczema, wherein the composition comprises a medium-chain triglyceride and 2'-fucosylated lactose, and the mass ratio of the medium-chain triglyceride to the 2'-fucosylated lactose is from 0.417 to 15.

[0012] After extensive research, the inventors unexpectedly discovered a synergistic effect between medium- and long-chain fatty acid triglycerides and 2'-fucosylated lactose when used in a specific ratio as described above. Specifically, the inventors found that using medium- and long-chain fatty acid triglycerides alone did not show significant efficacy in relieving allergies and / or improving eczema. However, when medium- and long-chain fatty acid triglycerides and 2'-fucosylated lactose were used in a specific mass ratio of 0.417 to 15, the resulting composition was significantly more effective in relieving allergies and / or improving eczema than the sum of the effects of using either ingredient alone, indicating a synergistic effect within this mass ratio range. This discovery could not have been reasonably expected based on existing technology. Attached Figure Description

[0013] To more clearly illustrate the technical solution of the present invention, the accompanying drawings required for describing the embodiments will be briefly described below. It should be understood that these drawings are only for the purpose of facilitating a better understanding of the present invention by those skilled in the art, and are not intended to limit the scope of the present invention.

[0014] Figure 1 This is a statistical graph showing the trypsin content in zebrafish after sample treatment. The results are compared to the model control group. This indicates that p < 0.05. This indicates that p < 0.001.

[0015] Figure 2 This is a typical graph showing the total movement distance of zebrafish after sample treatment. The black line represents the slow movement distance, the green line represents the medium movement distance, and the red line represents the fast movement distance.

[0016] Figure 3This is a statistical graph showing the total movement distance of zebrafish after sample treatment. The distance is compared with the model control group. This indicates that p < 0.05. This indicates that p < 0.01. This indicates that p < 0.001. Detailed Implementation

[0017] To make the objectives, technical solutions, and beneficial effects of this invention clearer, the invention will be described in detail below. It should be noted that the various aspects, features, embodiments, and advantages described in this invention are compatible and / or can be combined together.

[0018] Unless otherwise specified, the technical or scientific terms used in this specification have the same meaning as commonly understood by those skilled in the art.

[0019] In this invention, "and / or" has the meaning commonly understood in the art, for example, "A and / or B" covers A, B, and A and B.

[0020] In this invention, the term "medium-chain fatty acid" refers to fatty acids with 6-12 carbon atoms in their carbon chain, such as hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, etc.

[0021] In this invention, the term "long-chain fatty acid" refers to fatty acids with 14 or more carbon atoms in their carbon chain, generally 14-30 carbon atoms, such as myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid.

[0022] In this invention, the terms "medium-chain fatty acid triglyceride" and "long-chain fatty acid triglyceride" refer to the esterification products of "medium-chain fatty acid" and "long-chain fatty acid" with glycerol, respectively.

[0023] In this invention, the term "medium- and long-chain triglycerides" (or MLCT) refers to a class of triglycerides that contain both medium-chain and long-chain fatty acid residues in their molecular structure. MLCT is not equivalent to a physical mixture of long-chain triglycerides (LCT) and medium-chain triglycerides (MCT) (nor is it equivalent to a simple mixture of long-chain and medium-chain fatty acids), the latter lacking the physicochemical properties, metabolic characteristics, and nutritional value of MLCT. According to the relevant provisions of the "Regulations on the Administration of New Resource Foods," MLCT is produced from edible vegetable oils and medium-chain triglycerides through transesterification via lipase, followed by distillation, decolorization, and deodorization processes.

[0024] In this invention, the term "2'-fucosylated lactose" (or 2'-FL) refers to a human milk oligosaccharide with the molecular formula C2. 18 H 32 O 15 And its molecular weight is 488.439 g / mol.

[0025] In this invention, the various components can be used either in pure form or in impure form rich in them.

[0026] The present invention will now be described in detail.

[0027] This invention relates to the use of a composition in the preparation of a product for relieving allergies and / or improving eczema, wherein the composition comprises a medium- and long-chain fatty acid triglyceride and 2'-fucosylated lactose, and the mass ratio of the medium- and long-chain fatty acid triglyceride to the 2'-fucosylated lactose is 0.417 to 15.

[0028] After conducting extensive research, the inventors unexpectedly discovered that when long-chain fatty acid triglycerides and 2'-fucosylated lactose are used in combination at a mass ratio of 0.417 to 15, a synergistic effect is produced between them, which can significantly relieve allergies and / or improve eczema, showing good application prospects.

[0029] In some embodiments, the mass ratio of the medium- and long-chain fatty acid triglycerides to the 2'-fucosylated lactose is 2.5 to 15.

[0030] In some embodiments, the mass ratio of the medium- and long-chain fatty acid triglycerides to the 2'-fucosylated lactose is 3.76 to 15.

[0031] In some embodiments, the mass ratio of the medium- and long-chain fatty acid triglycerides to the 2'-fucosylated lactose is 5 to 15.

[0032] In some embodiments, the mass ratio of the medium- and long-chain fatty acid triglycerides to the 2'-fucosylated lactose is 7.5 to 15.

[0033] This invention does not have any particular requirements for the medium- and long-chain fatty acid triglycerides used; commonly used medium- and long-chain fatty acid triglycerides in the art can be used. Medium- and long-chain fatty acid triglycerides can be used in pure form or in a non-pure form rich in them.

[0034] The medium- and long-chain fatty acid triglyceride components contained in the compositions of the present invention may be a single medium- and long-chain fatty acid triglyceride (i.e., each molecular chain has the same long-chain fatty acid residues and the same medium-chain fatty acid residues), or may be a mixture of two or more medium- and long-chain fatty acid triglycerides with different compositions (i.e., each molecular chain has different long-chain fatty acid residues and / or different medium-chain fatty acid residues).

[0035] In some embodiments, the medium- and long-chain fatty acid triglycerides used in this invention contain C6-C6. 12 (e.g., C6, C7, C8, C9, C) 10 C 11 C 12 Medium-chain fatty acid residues and C (within the range defined by either or both) 14 -C 30 (e.g., C) 14 C 15 C 16 C 17 C 18 C 19 C 20 C 21 C 22 C 23 C 24 C 25 C 26 C 27 C 28 C 29 C 30 (or the range defined by either or both) long-chain fatty acid residues. The C6-C 12 The medium-chain fatty acid residues may be derived from one or more of the following: hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, etc., preferably hexanoic acid, octanoic acid, decanoic acid, and lauric acid. The C 14 -C 30 Long-chain fatty acid residues may be derived from one or more of the following: myristic acid, palmitic acid, heptadecanic acid, oleic acid, linoleic acid, stearic acid, nonadecanic acid, eicosapentaenoic acid, docosahexaenoic acid, docosapatraenoic acid, docosahexaenoic acid, tricarboxylic acid, docosapetraenoic acid, docosapatraenoic acid, docosahexaenoic acid, arachidonic acid, etc., preferably myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapatraenoic acid, and docosahexaenoic acid.

[0036] In some embodiments, the C6-C of the medium- and long-chain fatty acid triglycerides 12 medium-chain fatty acid residues on the C 14 -C 30The weight ratio of long-chain fatty acid residues is 0.124 to 2.000. As an example, said C6-C 12 The weight ratio of medium-chain fatty acid residues to said C 14 -C 30 long-chain fatty acid residues may be 0.124, 0.125, 0.130, 0.140, 0.150, 0.160, 0.170, 0.180, 0.190, 0.200, 0.300, 0.400, 0.500, 0.600, 0.700, 0.800, 0.900, 1.000, 1.100, 1.200, 1.300, 1.400, 1.500, 1.600, 1.700, 1.800, 1.900, 2.000, or a range defined by any two thereof.

[0037] Said product comprises or may be a medicament, and can be prepared by methods conventionally employed in the art.

[0038] Unless otherwise specified, the amounts and ratios of the respective components herein are all calculated based on the amount of their corresponding active substances.

[0039] Examples

[0040] In order to make the purposes, technical solutions and advantages of the present invention clearer, the present invention is further described in detail below with reference to the examples. It should be understood that the specific examples described herein are only used to explain the present invention, and are not intended to limit the present invention. Furthermore, those skilled in the art can easily understand that unless otherwise specified, the operation steps can be carried out by methods conventionally used in the art.

[0041] laboratory animals

[0042] Zebrafish are all raised in fish breeding water at 28°C (water quality: 200 mg of instant sea salt is added to every 1 L of reverse osmosis water, with an electrical conductivity of 450~550 μS / cm; a pH of 6.5~8.5; a hardness of 50~100 mg / L CaCO3), which are bred and provided by the fish breeding center of Hangzhou Hunter Biotechnology Co., Ltd. The license number for the use of experimental animals is: SYXK (Zhejiang) 2022-0004, the feeding and management meet the requirements of international AAALAC accreditation (accreditation number: 001458), and the IACUC ethical review number is: IACUC-2025-202510290008-01.

[0043] Instruments, consumables and reagents

[0044] Dissecting microscope (SZX7, OLYMPUS, Japan);

[0045] CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd.);

[0046] Precision electronic balance (CP214, OHAUS, USA);

[0047] 6-well plate (Zhejiang Beilanbo Biotechnology Co., Ltd.);

[0048] 96-well plate (Nest Biotech);

[0049] Fully automatic rapid sample grinder (JXFSTPRP-24L, Shanghai Jingxin Experimental Equipment Technology Department);

[0050] High-speed refrigerated centrifuge (Heraeus Fresco 17, ThermoFisher, Germany);

[0051] Multifunctional microplate reader (SPARK, TECAN, Austria);

[0052] Behavioral analyzer (Zebra Lab 3.22.3.31, Viewpoint, France).

[0053] Dimethyl sulfoxide (DMSO, batch number 20250624, Sinopharm Chemical Reagent Co., Ltd.);

[0054] PBS Phosphate Buffered Solution (dry powder) (lot number 20250730, Biosharp, China);

[0055] Zebrafish trypsin (TPS) enzyme-linked immunosorbent assay kit (catalog number ml286418V, Shanghai Enzyme-Link Biotechnology Co., Ltd.);

[0056] BCA Protein Concentration Assay Kit (Batch No. 20F05A97, Boster Biological Engineering Co., Ltd.);

[0057] 2,4-Dinitrochlorobenzene (DNCB, batch number F2518064, Shanghai Aladdin Biochemical Technology Co., Ltd.);

[0058] The medium- and long-chain fatty acid triglycerides were derived from medium- and long-chain fatty acid edible oil (production batch number 20250804) supplied by Yihai Kerry, with a purity of 61%.

[0059] 2'-Fucose-based lactose was produced by Hongmo Biotechnology (Shanghai) Co., Ltd. (batch number: Z006202412002) with a purity of 99.9%.

[0060] Loratadine, tablets, supplied by Peking University Medicine Co., Ltd. (batch number 241203).

[0061] Determination of maximum detectable concentration (MTC)

[0062] Wild-type AB strain zebrafish, 4 days post-fertilization (4 dpf), were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well (experimental group). Water-soluble samples were administered (concentrations shown in Table 1). A normal control group and a model control group were also included, with a volume of 3 mL per well. Except for the normal control group, each experimental group was treated with water-soluble DNCB (2,4-dinitrochlorobenzene) to establish a zebrafish eczema model. After treatment at 28°C for 21 hours, except for the normal control group, each experimental group was treated with a high concentration of water-soluble DNCB and treated at 28°C for another 3 hours. The MTC of the samples in the model zebrafish was then measured.

[0063] Table 1. Experimental results of maximum detectable concentration (MTC) of samples (n=30)

[0064]

[0065] The MTC experimental results in Table 1 show that, under the experimental conditions, medium- and long-chain fatty acid triglycerides and 2'-fucosylated lactose did not cause death or abnormal phenotypes in zebrafish at concentrations up to 2000 μg / mL, indicating that both exhibit good safety within this concentration range. Therefore, the highest concentration (2000 μg / mL) used in the efficacy evaluation experiments below is within the safe range, ensuring the reliability of the efficacy evaluation results.

[0066] Evaluation of the efficacy of the sample in improving eczema (trypsin content)

[0067] Wild-type AB strain zebrafish (4 dpf) were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well (experimental group). Water-soluble samples (concentrations shown in Table 2) were administered, along with a positive control of loratadine at a concentration of 187.5 ng / mL. A normal control and a model control group were also included, with a volume of 3 mL per well. Three replicate experiments were conducted, with 90 zebrafish per replicate. Except for the normal control group, each experimental group received water-soluble DNCB (2,4-dinitrochlorobenzene) to establish a zebrafish eczema model. After treatment at 28℃ for 21 hours, except for the normal control group, each experimental group received a high concentration of water-soluble DNCB and continued treatment at 28℃ for another 3 hours. Zebrafish samples were collected according to the trypsin-like enzyme kit instructions. Data were collected using a multi-functional microplate reader to analyze the trypsin content in each zebrafish group. Statistical analysis of this index was used to evaluate the efficacy of the samples in improving eczema, especially allergy relief. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated statistical significance.

[0068] Then, for each embodiment and comparative example, the reduction in trypsin content compared to the model control group was calculated (denoted as A), and for each embodiment, the sum of the reductions in trypsin content compared to the model control group for the corresponding comparative example was calculated (denoted as B); for example, for Example 1 (MLCT concentration 500 μg / mL + 2'-FL concentration 133 μg / mL), the "sum of reductions in trypsin content compared to the model control group for the corresponding comparative example" is the sum of the "reductions in trypsin content compared to the model control group" for Comparative Example 1 (MLCT concentration 500 μg / mL) and Comparative Example 4 (2'-FL concentration 133 μg / mL). Finally, the synergy coefficient (C=A / B) was calculated. When the synergy coefficient > 1, a synergistic effect exists; the larger the value, the stronger the synergistic effect.

[0069] Following the above method, zebrafish were administered medium- and long-chain triglycerides (MLCT) and 2'-fucosylated lactose (2'-FL) at different ratios to evaluate their efficacy in alleviating allergies. The dosages are shown in Table 2. The results are shown in Table 2 and... Figure 1 As shown.

[0070] Table 2. Experimental results evaluating the efficacy of the samples in improving eczema (trypsin content).

[0071]

[0072] Note: Compared with the model control group, This indicates that p < 0.05. This indicates that p < 0.001.

[0073] In Table 2, the correspondence between Examples 1-8 and the comparative examples is as follows:

[0074] Example 1 (MLCT 500 μg / mL + 2'-FL 133 μg / mL) corresponds to: Comparative Example 1 (MLCT 500 μg / mL) + Comparative Example 4 (2'-FL 133 μg / mL)

[0075] Example 2 (MLCT 500 μg / mL + 2'-FL 1200 μg / mL) corresponds to: Comparative Example 1 (MLCT 500 μg / mL) + Comparative Example 6 (2'-FL 1200 μg / mL)

[0076] Example 3 (MLCT 1000 μg / mL + 2'-FL 133 μg / mL) corresponds to: Comparative Example 2 (MLCT 1000 μg / mL) + Comparative Example 4 (2'-FL 133 μg / mL)

[0077] Example 4 (MLCT 1000 μg / mL + 2'-FL 400 μg / mL) corresponds to: Comparative Example 2 (MLCT 1000 μg / mL) + Comparative Example 5 (2'-FL 400 μg / mL)

[0078] Example 5 (MLCT 1000 μg / mL + 2'-FL 1200 μg / mL) corresponds to: Comparative Example 2 (MLCT 1000 μg / mL) + Comparative Example 6 (2'-FL 1200 μg / mL)

[0079] Example 6 (MLCT 2000 μg / mL + 2'-FL 133 μg / mL) corresponds to: Comparative Example 3 (MLCT 2000 μg / mL) + Comparative Example 4 (2'-FL 133 μg / mL)

[0080] Example 7 (MLCT 2000 μg / mL + 2'-FL 400 μg / mL) corresponds to: Comparative Example 3 (MLCT 2000 μg / mL) + Comparative Example 5 (2'-FL 400 μg / mL)

[0081] Example 8 (MLCT 2000 μg / mL + 2'-FL 1200 μg / mL) corresponds to: Comparative Example 3 (MLCT 2000 μg / mL) + Comparative Example 6 (2'-FL 1200 μg / mL)

[0082] From Table 2 and Figure 1 The results showed that, compared with the normal control group, the trypsin content of wild-type AB strain zebrafish in the model control group (4dpf) induced by DNCB water-soluble administration was significantly increased (p<0.05), indicating that the DNCB-induced zebrafish eczema model was successfully established. The positive control drug (loratadine), single-component 2'-FL (133 μg / mL, 400 μg / mL, and 1200 μg / mL), and Examples 1-8 all significantly improved eczema, especially alleviating allergies, specifically manifested in a significant decrease in trypsin content compared with the model control group (p<0.05). That is, single-component 2'-FL has the effect of improving eczema; when MLCT and 2'-FL are used in combination at a mass ratio of 0.417 to 15, the combination also has the effect of improving eczema.

[0083] As shown in Comparative Examples 1-3 above, MLCT alone, within a concentration range of 500-2000 μg / mL, failed to significantly reduce the trypsin content in zebrafish, indicating that MLCT alone does not have a significant effect on improving eczema. However, when MLCT was used in combination with 2'-FL at a mass ratio of 0.417 to 15, Examples 1-8 all showed significant effects on improving eczema.

[0084] More importantly, the reduction in trypsin content in all examples was greater than the sum of the reductions of the individual components, indicating a synergistic effect between MLCT and 2'-FL in improving eczema, especially allergy relief. Specifically, Example 1 (MLCT to 2'-FL mass ratio of 3.76) is equivalent to a combination of Comparative Example 1 (single component MLCT 500 µg / mL) and Comparative Example 4 (single component 2'-FL 133 µg / mL). Compared to the model control group, the reduction in trypsin content in Example 1 was 1.09, while the reductions in trypsin content in Comparative Examples 1 and 4 were 0.02 and 0.72, respectively. The former was greater than the sum of the latter two (0.74), and the synergistic coefficient was 1.473 (i.e., 1.09 / 0.74 = 1.473), indicating a synergistic effect in improving eczema, especially allergy relief. Similarly, Examples 2-8 also showed a synergistic effect in improving eczema, especially allergy relief. That is, when the mass ratio of MLCT to 2'-FL is 0.417 to 15, the two have a synergistic effect in improving eczema, especially in relieving allergies.

[0085] Furthermore, Examples 3 and 6 (MLCT to 2'-FL mass ratio of 7.5 to 15) have a larger synergistic coefficient compared to other Examples (MLCT to 2'-FL mass ratio of 0.417 to 5), indicating that the synergistic effect of the two on improving eczema, especially relieving allergies, is more significant at this mass ratio (7.5 to 15).

[0086] Evaluation of the efficacy of the sample in improving eczema (behavioral (pruritus))

[0087] Wild-type AB strain zebrafish (4 dpf) were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well (experimental group). Water-soluble samples (concentrations shown in Table 3) were administered, along with a positive control of loratadine at a concentration of 187.5 ng / mL. A normal control group and a model control group were also included, with a volume of 3 mL per well. Except for the normal control group, each experimental group received water-soluble DNCB to establish a zebrafish eczema model. After treatment at 28℃ for 21 hours, except for the normal control group, each experimental group received a high concentration of water-soluble DNCB and continued treatment at 28℃ for another 3 hours. Ten zebrafish from each group were then randomly selected and placed in 96-well plates (1 zebrafish / well, 200 μL / well). Behavioral data were collected for 20 minutes using a behavioral analyzer, and the total movement distance of the zebrafish was analyzed. Statistical analysis of this indicator was used to evaluate the efficacy of the samples in improving eczema, especially relieving itching. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated statistical significance.

[0088] Then, the reduction in total movement distance of each embodiment and comparative embodiment compared to the model control group is calculated; and for each embodiment, the sum of the reduction in total movement distance of the corresponding comparative embodiment compared to the model control group is calculated; subsequently, the synergy coefficient is calculated, as described above.

[0089] Following the above method, zebrafish were administered MLCT and 2'-FL at different ratios to evaluate their efficacy in improving eczema. The dosages are shown in Table 3. The results are also shown in Table 3. Figure 2 and Figure 3 As shown.

[0090] Table 3. Results of the experiment evaluating the efficacy of the samples in improving eczema (behavioral (pruritus)).

[0091]

[0092] Note: Compared with the model control group, This indicates that p < 0.05. This indicates that p < 0.01. This indicates that p < 0.001.

[0093] In Table 3, the correspondence between Examples 1-8 and the comparative examples is as follows:

[0094] Example 1 (MLCT 500 μg / mL + 2'-FL 133 μg / mL) corresponds to: Comparative Example 1 (MLCT 500 μg / mL) + Comparative Example 4 (2'-FL 133 μg / mL)

[0095] Example 2 (MLCT 500 μg / mL + 2'-FL 1200 μg / mL) corresponds to: Comparative Example 1 (MLCT 500 μg / mL) + Comparative Example 6 (2'-FL 1200 μg / mL)

[0096] Example 3 (MLCT 1000 μg / mL + 2'-FL 133 μg / mL) corresponds to: Comparative Example 2 (MLCT 1000 μg / mL) + Comparative Example 4 (2'-FL 133 μg / mL)

[0097] Example 4 (MLCT 1000 μg / mL + 2'-FL 400 μg / mL) corresponds to: Comparative Example 2 (MLCT 1000 μg / mL) + Comparative Example 5 (2'-FL 400 μg / mL)

[0098] Example 5 (MLCT 1000 μg / mL + 2'-FL 1200 μg / mL) corresponds to: Comparative Example 2 (MLCT 1000 μg / mL) + Comparative Example 6 (2'-FL 1200 μg / mL)

[0099] Example 6 (MLCT 2000 μg / mL + 2'-FL 133 μg / mL) corresponds to: Comparative Example 3 (MLCT 2000 μg / mL) + Comparative Example 4 (2'-FL 133 μg / mL)

[0100] Example 7 (MLCT 2000 μg / mL + 2'-FL 400 μg / mL) corresponds to: Comparative Example 3 (MLCT 2000 μg / mL) + Comparative Example 5 (2'-FL 400 μg / mL)

[0101] Example 8 (MLCT 2000 μg / mL + 2'-FL 1200 μg / mL) corresponds to: Comparative Example 3 (MLCT 2000 μg / mL) + Comparative Example 6 (2'-FL 1200 μg / mL)

[0102] From Table 3, Figure 2 and Figure 3 The results showed that, compared with the normal control group, the total movement distance of wild-type AB strain zebrafish in the model control group after induction with DNCB water-soluble treatment was significantly increased (p<0.05), indicating that the zebrafish eczema model induced by DNCB was successfully established. The positive control drug (loratadine), single-component 2'-FL (400 μg / mL and 1200 μg / mL), and Examples 1-8 all significantly improved eczema, especially relieving itching, specifically manifested as a significant reduction in total movement distance compared with the model control group (p<0.05). That is, single-component 2'-FL has the effect of improving eczema; when MLCT and 2'-FL are used in combination at a mass ratio of 0.417 to 15, the combination of the two has the effect of improving eczema.

[0103] As shown in Comparative Examples 1-3 above, MLCT alone, within a concentration range of 500-2000 μg / mL, failed to significantly reduce the total movement distance of zebrafish, indicating that MLCT alone does not have a significant effect on improving eczema. However, when MLCT was used in combination with 2'-FL at a mass ratio of 0.417 to 15, Examples 1-8 all showed significant effects on improving eczema.

[0104] More importantly, the reduction in total movement distance in all examples was greater than the sum of the reductions of the individual components, indicating a synergistic effect between MLCT and 2'-FL in improving eczema, especially in relieving itching. Specifically, Example 1 (MLCT to 2'-FL mass ratio of 3.76) is equivalent to a combination of Comparative Example 1 (single-component MLCT 500 µg / mL) and Comparative Example 4 (single-component 2'-FL 133 µg / mL). Compared with the model control group, Example 1 showed a reduction of 424 in total movement distance, while Comparative Example 1 and Comparative Example 4 showed reductions of 38 and 340, respectively. The former was greater than the sum of the latter two (378), and the synergy coefficient was 1.122 (i.e., 424 / 378 = 1.122), indicating a synergistic effect of Example 1 in improving eczema, especially in relieving itching. Similarly, Examples 2-8 also showed a synergistic effect in improving eczema, especially in relieving itching. That is, when the mass ratio of MLCT to 2'-FL is 0.417 to 15, the two have a synergistic effect in improving eczema, especially in relieving itching.

[0105] Furthermore, Examples 1, 3, 4, 6 and 7 (MLCT to 2'-FL mass ratio of 2.5 to 15) had a larger synergistic coefficient than Examples 2, 5 and 8 (MLCT to 2'-FL mass ratio of 0.417 to 1.67), indicating that the synergistic effect of the two on improving eczema, especially relieving itching, was more significant at this mass ratio (2.5 to 15).

[0106] Furthermore, Examples 1, 3, 6, and 7 (MLCT to 2'-FL mass ratio of 3.76 to 15) had a larger synergistic coefficient than Examples 2, 4, 5, and 8 (MLCT to 2'-FL mass ratio of 0.417 to 2.5), indicating that the synergistic effect of the two on improving eczema, especially relieving itching, was more significant at this mass ratio (3.76 to 15).

[0107] Furthermore, Examples 3, 6, and 7 (MLCT to 2'-FL mass ratio of 5 to 15) had a larger synergistic coefficient compared to Examples 1, 2, 4, 5, and 8 (MLCT to 2'-FL mass ratio of 0.417 to 3.76), indicating that the synergistic effect of the two on improving eczema, especially relieving itching, was more significant at this mass ratio (5 to 15).

[0108] Furthermore, Examples 3 and 6 (MLCT to 2'-FL mass ratio of 7.5 to 15) had a larger synergistic coefficient compared to Examples 1, 2, 4, 5, 7 and 8 (MLCT to 2'-FL mass ratio of 0.417 to 5), indicating that the synergistic effect of the two on improving eczema, especially relieving itching, was more significant at this mass ratio (7.5 to 15).

[0109] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of the composition in the preparation of a product for improving eczema, wherein the composition comprises a medium-chain fatty acid triglyceride and 2'-fucosylated lactose, and the mass ratio of the medium-chain fatty acid triglyceride to the 2'-fucosylated lactose is from 0.417 to 15.

2. The use according to claim 1, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the 2'-fucosylated lactose is 2.5 to 15.

3. The use according to claim 2, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the 2'-fucosylated lactose is 3.76 to 15.

4. The use according to claim 3, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the 2'-fucosylated lactose is 5 to 15.

5. The use according to claim 4, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the 2'-fucosylated lactose is 7.5 to 15.

6. The use according to claim 1, characterized in that, The composition consists of medium- and long-chain fatty acid triglycerides and 2'-fucosylated lactose.

7. The use according to claim 1, wherein the eczema is allergic eczema.

Images